Key License-Out Drugs in China in the Last Decade

In the last decade, China's biopharmaceutical sector has seen remarkable growth, particularly in the licensing out of key drugs, as evidenced by significant deals such as the acquisition of GenScript Biotech Corporation by AstraZeneca and the collaboration between BeiGene and Novartis on Tislelizumab.

These transactions not only underscore China's rising influence and innovation in the global biopharma landscape but also highlight the substantial financial implications, with milestone payments and sales shares reflecting the international market's recognition of the value of Chinese biopharma assets, as seen in the deal between Legend Biotech and Johnson & Johnson for LCAR-B38M, which includes a $1.165 billion milestone payment plus a sales share.